HUM 📈 Humana - Overview
Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US4448591028
HUM: Medical Insurance, Specialty Insurance, Pharmacy Benefits, Home Care Services
Humana Inc. is a prominent player in the US health insurance market, offering a wide range of medical and specialty insurance products to individuals and groups. The company's operations are divided into two main segments: Insurance and CenterWell. Through these segments, Humana provides medical and supplemental benefit plans to individuals, including those eligible for Medicare and Medicaid. Its contract with the Centers for Medicare and Medicaid Services enables the company to administer the Limited Income Newly Eligible Transition prescription drug plan program, while contracts with various states allow it to provide Medicaid, dual eligible, and long-term support services benefits.
In addition to its government-sponsored plans, Humana offers commercial fully-insured medical and specialty health insurance benefits, including dental, vision, life insurance, and other supplemental health benefits. The company also provides administrative services only products to individuals and employer groups, allowing them to customize their health insurance plans. Furthermore, Humana has a significant presence in the military services sector, with contracts such as the TRICARE T2017 East Region contract. Its pharmacy benefit manager business and operations of pharmacies and senior-focused primary care centers also contribute to its diversified revenue streams.
Humana's product offerings are complemented by its home solutions services, which include home health, hospice, and other services. These services are available not only to the company's health plan members but also to third parties. In terms of distribution, Humana sells its products through a variety of channels, including employers and employees, independent brokers and agents, sales representatives, and digital insurance agencies. With a history dating back to 1961, Humana has established itself as a major player in the US health insurance market, with its headquarters located in Louisville, Kentucky.
From a financial perspective, Humana is a publicly traded company listed on the New York Stock Exchange (NYSE) under the ticker symbol HUM. Its common stock is classified under the GICS Sub Industry of Managed Health Care, with an ISIN of US4448591028. As a leading managed health care provider, Humana is committed to providing high-quality, affordable health insurance products and services to its members. With a strong online presence, including its website at https://www.humana.com, the company is well-positioned to continue serving the evolving needs of the US health insurance market.
Additional Sources for HUM Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
HUM Stock Overview
Market Cap in USD | 33,007m |
Sector | Healthcare |
Industry | Healthcare Plans |
GiC Sub-Industry | Managed Health Care |
IPO / Inception | 1993-01-22 |
HUM Stock Ratings
Growth 5y | -35.2% |
Fundamental | 14.7% |
Dividend | 46.2% |
Rel. Strength Industry | -6815 |
Analysts | 3.6/5 |
Fair Price Momentum | 230.60 USD |
Fair Price DCF | 639.64 USD |
HUM Dividends
Dividend Yield 12m | 1.34% |
Yield on Cost 5y | 1.01% |
Annual Growth 5y | 7.20% |
Payout Consistency | 54.7% |
HUM Growth Ratios
Growth Correlation 3m | 4.9% |
Growth Correlation 12m | -65.6% |
Growth Correlation 5y | 5.6% |
CAGR 5y | -5.49% |
CAGR/Mean DD 5y | -0.38 |
Sharpe Ratio 12m | -1.22 |
Alpha | -67.66 |
Beta | 0.94 |
Volatility | 30.08% |
Current Volume | 1736.9k |
Average Volume 20d | 1862.6k |
As of January 07, 2025, the stock is trading at USD 264.29 with a total of 1,736,896 shares traded.
Over the past week, the price has changed by +4.31%, over one month by -5.86%, over three months by +12.24% and over the past year by -41.99%.
Neither. Based on ValueRay Fundamental Analyses, Humana is currently (January 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of 14.69 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of HUM as of January 2025 is 230.60. This means that HUM is currently overvalued and has a potential downside of -12.75%.
Humana has received a consensus analysts rating of 3.60. Therefor, it is recommend to hold HUM.
- Strong Buy: 7
- Buy: 1
- Hold: 17
- Sell: 0
- Strong Sell: 0
According to ValueRays Forecast Model, HUM Humana will be worth about 252.2 in January 2026. The stock is currently trading at 264.29. This means that the stock has a potential downside of -4.58%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 288.2 | 9% |
Analysts Target Price | 587.5 | 122.3% |
ValueRay Target Price | 252.2 | -4.6% |